501. Non-leukemic autologous reconstitution after allogeneic bone marrow transplantation for Ph-positive chronic myelogenous leukemia: Extended remission preceding eventual relapse
- Author
-
Jeffrey S. Miller, Daniel J. Weisdorf, P B McGlave, Catherine M. Verfaillie, Betsy A. Hirsch, Claudio G. Brunstein, and Ronald C. McGlennen
- Subjects
Adult ,Male ,medicine.medical_specialty ,Cyclophosphamide ,Transplantation Chimera ,Myelogenous ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,medicine ,Humans ,Preparative Regimen ,Bone Marrow Transplantation ,Transplantation ,business.industry ,Graft Survival ,Infant ,Hematology ,Total body irradiation ,Middle Aged ,medicine.disease ,Hematopoietic Stem Cells ,Surgery ,Leukemia ,medicine.anatomical_structure ,Treatment Outcome ,Child, Preschool ,Female ,Bone marrow ,business ,Chronic myelogenous leukemia ,medicine.drug - Abstract
Autologous reconstitution is the recovery of autologous hematopoietic function after failure of an allogeneic graft to establish sustained hematopoiesis either with or without preceding donor engraftment. We reviewed 9 years experience of the University of Minnesota and identified 10 of 291 patients who underwent allogeneic BMT for Ph-positive CML and developed non-leukemic autologous reconstitution. All patients received the same preparative regimen with cyclophosphamide and total body irradiation. Eight patients had a 6/6-antigen matched donor. Eight patients received their graft from an unrelated donor. In five cases the graft was T cell-depleted. Non-malignant autologous reconstitution initially manifested as mixed chimerism in nine of 10 patients and lasted for a median of 11 (3-41) months. Eight patients have relapsed and four are still alive. The two relapse-free patients have died 24 and 48 months post transplant. Of the four surviving patients, two are in interferon-induced cytogenetic remission at 53+ and 101+ months of follow-up. Autologous non-leukemic reconstitution is uncommon, but appears to be a distinct clinical syndrome, perhaps occurring more frequently after unrelated donor BMT. Although usually followed by relapse, relapse-free survival may be prolonged. ispartof: Bone marrow transplantation vol:26 issue:11 pages:1173-7 ispartof: location:England status: published